Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Neurology
Published in: Current Treatment Options in Neurology 3/2013

01-06-2013 | NEUROIMMUNOLOGY (RP LISAK, SECTION EDITOR)

Guillain-Barré Syndrome

Authors: Mazen M. Dimachkie, M.D, Richard J. Barohn, M.D

Published in: Current Treatment Options in Neurology | Issue 3/2013

Login to get access

Opinion statement

Acute Inflammatory polyneuropathies are an important group of neuromuscular disorders and are referred to collectively as Guillain-Barré syndrome (GBS). Our knowledge regarding pathogenesis, diagnosis and management continues to expand, resulting in improved opportunities for identification and treatment. These autoimmune processes cause neuropathy by affecting various structures (myelin or axons), at different locations (nerve root, nerve cell bodies or peripheral nerve) with a variety of patterns. Most clinical neurologists will be involved in the management of patients with these disorders, and there are now a variety of reasonable therapies available for acquired demyelinating neuropathies. In this report, we review the distinctive clinical, laboratory and electro-diagnostic features that aid in their diagnosis, with emphasis on clinical characteristics that are of paramount importance in diagnosing specific conditions and determining the most appropriate therapies, and helpful in determining long-term prognosis.
Literature
1.
2.
Ropper AH, Wijdicks EFM, Truax BT. In: FA Davis Comp (ed.) Guillain-Barré Syndrome, Contemporary Neurology Series 34, Philadelphia, PA, 1991.
3.
4.
5.
Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis. 1997;176 Suppl 2:S92–8.PubMedCrossRef
6.
Van Koningsveld R, Van Doorn PA, Schmitz PI, Ang CW, Van der Meché FG. Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands. Neurology. 2000;54(3):620–5.PubMedCrossRef
7.
Govoni V, Granieri E. Epidemiology of the Guillain-Barré syndrome. Curr Opin Neurol. 2001;14(5):605–13.PubMedCrossRef
8.
McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32(2):150–63.PubMedCrossRef
9.
Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neuro. 1998;44(5):780–8.CrossRef
10.
McKhann GM, Cornblath DR, Ho T, et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 1991;7;338(8767):593-597.
11.
McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993;33(4):333–42.PubMedCrossRef
12.
Ogawara K, Kuwabara S, Mori M, et al. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol. 2000;48(4):624–31.PubMedCrossRef
13.
Paradiso G, Tripoli J, Galicchio S, Fejerman N. Epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barré syndrome: a reappraisal. Ann Neurol. 1999;46(5):701–7.PubMedCrossRef
14.
Barohn RJ, Saperstein DS. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. Semin Neurol. 1998;18(1):49–61.PubMedCrossRef
15.
Ruts L, Drenthen J, Jacobs BC, van Doorn PA, Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology. 2010;74(21):1680–6.PubMedCrossRef
16.
Dionne A, Nicolle MW, Hahn AF. Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy. Muscle Nerve. 2010;41(2):202–7.PubMed
17.
Fisher CM. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956;255:57–65.PubMedCrossRef
18.
Overell JR, Hsieh ST, Odaka M, Yuki N, Willison HJ. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database Syst Rev. 2007;1, CD004761.PubMed
19.
20.
Ito M, Kuwabara S, Odaka M, et al. Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J Neurol. 2008;255(5):674–82.PubMedCrossRef
21.
Yuki N, Sato S, Tsuji S, Hozumi I, Miyatake T. An immunologic abnormality common to Bickerstaff ’s brain stem encephalitis and Fisher’s syndrome. J Neurol Sci. 1993;118(1):83–7.PubMedCrossRef
22.
Odaka M, Yuki N, Yamada M, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain Barre syndrome. Brain. 2003;126:2279–90.PubMedCrossRef
23.
Ropper AH. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol. 1986;43:1150–2.PubMedCrossRef
24.
Ropper AH. Further regional variants of acute immune polyneuropathy. Bifacial weakness or sixth nerve paresis with paresthesias lumbar polyradiculopathy and ataxia with pharyngeal-cervical-brachial weakness. Arch Neurol. 1994;51(7):671–5.PubMedCrossRef
25.
Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol. 1996;39(1):17–28.PubMedCrossRef
26.
Ho TW, Mishu B, Li C. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118:597–605.PubMedCrossRef
27.
Allos BM. Association between Campylobacter infection and Guillain-Barré syndrome. J Infect Dis. 1997;176 suppl 2:S25–S127.
28.
Capasso M, Caporale CM, Pomilio F, et al. Acute motor conduction block neuropathy: another Gullain-Barre syndrome variant. Neurology. 2003;61:617–22.PubMedCrossRef
29.
Hafer-Macko C, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol. 1996;39:625–35.PubMedCrossRef
30.
Griffin JW, Li CY, Macko C, et al. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol. 1996;25:33–51.PubMedCrossRef
31.
Ho TW, Willison HJ, Nachamkin I, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol. 1999;45:168–73.PubMedCrossRef
32.
Magira EE, Papaioakim M, Nachamkin I, et al. Differential distribution of HLA-DQ beta/DR beta epitopes in the two forms of Guillain- Barré syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ beta epitopes associated with susceptibility to and protection from AIDP. J Immunol. 2003;170(60):3074–4080.PubMed
33.
Koga M, Yuki N, Takahashi M, Saito K, Hirata K. Close association of IgA anti-ganglioside antibodies with antecedent Campylobacter jejuni infection in Guillain-Barré and Fisher’s syndromes. J Neuroimmun. 1998;81(1–2):138–43.CrossRef
34.
Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol. 1979;110:10523.
35.
36.
Pritchard J, Mukherjee R, Hughes RA. Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunization. J Neurol Neurosurg Psychiatry. 2002;73(3):348–9.PubMedCrossRef
37.
Albers JW, Donofrio PD, McGonagle TK. Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 1985;8(6):528–39.PubMedCrossRef
38.
Van den Bergh PY, Piéret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2004;29(4):565–74.PubMedCrossRef
39.
Tamura N, Kuwabara S, Misawa S, Kanai K, Nakata M, Sawai S, et al. Time course of axonal regeneration in acute motor axonal neuropathy. Muscle Nerve. 2007;35(6):793–5.PubMedCrossRef
40.
Wiederholt WC, Mulder DW, Lambert EH. The Landry-Guillain-Barré-Srohl Syndrome or polyradiculoneuropathy. Historical Review, report on 97 cases and present concepts. Mayo Clin Proc. 1964;39:427–51.PubMed
41.
Oomes PG, Jacobs BC, Hazenberg MP, Bänffer JR, van der Meché FG. Anti-GM1 IgG antibodies and Campylobacter bacteria in Guillain-Barré syndrome: evidence of molecular mimicry. Ann Neurol. 1995;38(2):170–5.PubMedCrossRef
42.
Kuwabara S, Yuki N, Koga M, et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann Neuro. 1998;44(2):202–8.CrossRef
43.
Vriesendorp FJ, Mishu B, Blaser MJ, Koski CL. Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: correlation and prognosis. Ann Neurol. 1993;34(2):130–5.PubMedCrossRef
44.
Willison HJ, Veitch J, Paterson G, Kennedy PGE. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psych. 1993;56(2):204–6.CrossRef
45.
Yuki N, Sato S, Tsuji S, Ohsawa T, Miyatake T. Frequent presence of anti-GQ1b antibody in Fisher’s syndrome. Neurology. 1993;43(2):414–7.PubMedCrossRef
46.
Morgan GW, Barohn RJ, Bazan C, et al. Nerve root enhancement with MRI in inflammatory demyelinating polyradiculoneuropathy. Neurology. 1993;43(3 Pt 1):618–20.PubMedCrossRef
47.
Gorson KC, Ropper AH, Muriello MA, Blair R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barré syndrome. Neurology. 1996;47(3):813–7.PubMedCrossRef
48.
Hughes RA, Wijdicks EF, Benson E, et al. Multidisciplinary Consensus Group. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol. 2005;62(8):1194–8.PubMedCrossRef
49.
French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol. 1987;22:753–61.CrossRef
50.
The Guillain-Barré syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology. 1985;35(8):1096–104.CrossRef
51.
French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol. 1997;41:298–306.CrossRef
52.
Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291(19):2367–75.PubMedCrossRef
53.
van der Meché FG, Schmitz PI. and the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med. 1992;326:1123–9.PubMedCrossRef
54.
Plasma Exchange and Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin and combined treatments in Guillain-Barré syndrome. Lancet. 1997;349:225–30.CrossRef
55.
• Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol. 2010;30 Suppl 1:S9–14. Sialylated IgG Fcs are important for the in vivo activity of intravenous immunoglobulin. PubMedCrossRef
56.
Hughes RA. Plasma exchange versus intravenous immunoglobulin for Guillain-Barré syndrome. Ther Apher. 1997;1:129–30.PubMedCrossRef
57.
Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;61(6):736–40.PubMedCrossRef
58.
Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry. 1998;64(1):74–7.PubMedCrossRef
59.
McKhann GM, Griffin JW, Cornblath DR, et al. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol. 1988;23(4):347–53.PubMedCrossRef
60.
Dutch Guillain-Barré Study Group. Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Neurology. 1999;53(3):598–604.CrossRef
61.
van Koningsveld R, Steyerberg EW, Hughes RA, et al. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet. 2007;6(7):589–94.CrossRef
62.
•• Walgaard C, Lingsma HF, Ruts L, et al. Early recognition of poor prognosis in Gullain-Barre syndrome. Neurology. 2011;76(11):968–75. High age, preceding diarrhea, and low Medical Research Council sum score at 1 week were independently associated with being unable to walk at 4 weeks, 3 months, and 6 months. PubMedCrossRef
63.
Kuitwaard K, de Gelder J, Tio-Gillen AP, Hop WC, van Gelder T, van Toorenenbergen AW, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neuro. 2009;66(5):597–603.CrossRef
64.
Ho TW, Li CY, Cornblath DR, Gao CY, Asbury AK, Griffin JW, et al. Patterns of recovery in the Guillain-Barre syndromes. Neurology. 1997;48(3):695–700.PubMedCrossRef
65.
Ho TW, Hsieh ST, Nachamkin I, et al. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology. 1997;48:717–24.PubMedCrossRef
66.
Mori M, Kuwabara S, Fukutake T, Haltori T. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology. 2007;68(14):1144–6.PubMedCrossRef
Metadata
Title
Guillain-Barré Syndrome
Authors
Mazen M. Dimachkie, M.D
Richard J. Barohn, M.D
Publication date
01-06-2013
Publisher
Current Science Inc.
Published in
Current Treatment Options in Neurology / Issue 3/2013
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-013-0231-z

Other articles of this Issue 3/2013

Current Treatment Options in Neurology 3/2013 Go to the issue

NEURO-ONCOLOGY (NEOPLASMS) (MR ROSENFELD, SECTION EDITOR)

Anaplastic Oligodendroglioma: Advances and Treatment Options

NEURO-ONCOLOGY (NEOPLASMS) (MR ROSENFELD, SECTION EDITOR)

Treatment Options in Newly Diagnosed Glioblastoma

MULTIPLE SCLEROSIS AND RELATED DISORDERS (BM SEGAL, SECTION EDITOR)

Management of Secondary Progressive Multiple Sclerosis: Prophylactic Treatment—Past, Present, and Future Aspects

NEUROIMMUNOLOGY (RP LISAK, SECTION EDITOR)

Central Nervous System Vasculitis

MULTIPLE SCLEROSIS AND RELATED DISORDERS (BM SEGAL, SECTION EDITOR)

B-Cell Targeting Agents in the Treatment of Multiple Sclerosis

MULTIPLE SCLEROSIS AND RELATED DISORDERS (BM SEGAL, SECTION EDITOR)

Autologous Hematopoietic Stem Cell Transplantation as a Treatment Option for Aggressive Multiple Sclerosis